Join the Oncology Voice Network. Join for Free
The HIGH FIVE Challenge
Mel Robbins High Five Habit Tom Caravela MSL Talk Podcast High Five Challenge

The HIGH FIVE Challenge


Share This Article


Summary

In this episode, Tom Caravela delves into the transformative power of Mel Robbins' high five habit. He begins by introducing Mel Robbins and her background, then unpacks the concept and practical application of the high five habit. Tom discusses research and studies that validate its effectiveness, highlighting how it can positively impact daily intentions and mindset. The episode encourages listeners to undertake the high five challenge and invites them to share their personal experiences with this practice.

Tom Caravela, Managing Director of The Carolan Group and Host of the MSL Talk Podcast introduces the HIGH FIVE Habit and the HIGH FIVE Challenge.

Tom shares…

👉 Insights on the new book by @Mel Robbins, The High Five Habit

👉 What the High Five Habit is and how it works

👉 The research behind the movement and why you should consider it

👉 An invitation to the High Five Challenge

Click for Source
Mel Robbins, High Five Habit, Tom Caravela, MSL Talk Podcast, High Five Challenge

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Why Relationships Define Medical Affairs Leadership
OVN Avatar Kirk Shepard

Why Relationships Define Medical Affairs Leadership

Podcast
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How Medical Affairs Professionals Should Engage with Digital Opinion Leaders

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN